No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
78 |
4. Check minimum number of eventsNone |
78 |
5. Include endpoints |
88 |
6. Filter based on genotype QC (FinnGen only) |
88 |
Control definitions (FinnGen only)
- Control exclude
- E4_ENDOGLAND
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- E20-E35
- Name in latin
- Dysfunctio polyglandularis (endocrina)
Similar endpoints
↥List of similar endpoints to
Polyglandular dysfunction
based on the number of shared cases.
Similar with more cases:
- Disorders of other endocrine glands
- Endocrine, nutritional and metabolic diseases
- Any operation in hilmo
- Any event in hilmo or specialist outpatient
- Any prescribed medicine buy
Similar with less cases:
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 523 | 320 | 196 |
| Only index persons | 419 | 270 | 149 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.01 | 0.01 |
| Only index persons | 0.01 | 0.01 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 38.73 | 38.37 | 38.89 |
| Only index persons | 35.72 | 35.52 | 36.08 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 88 | 59 | 29 |
| Unadjusted period prevalence (%) | 0.02 | 0.02 | 0.01 |
| Median age at first event (years) | 33.88 | 37.10 | 27.34 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
No data
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 73
- Matched controls
- 730
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
H02AB09
ATC
hydrocortisone; systemic
175.3
31.6
31
*
H02AA02
ATC
fludrocortisone; oral
+∞
30.3
27
*
105
Kela drug reimbursment
Adrenal cortical hypofunction
+∞
29.1
26
*
E27.1
ICD-10 Finland
Primary adrenocortical insufficiency
+∞
25.5
23
*
E10.9
ICD-10 Finland
Type 1 diabetes mellitus, Without complications
32.5
23.5
31
16
E31.00
ICD-10 Finland
APECED syndrome
+∞
23.1
21
*
A11CC03
ATC
alfacalcidol; systemic
69.8
21.8
24
5
A10AE05
ATC
insulin detemir; parenteral
27.5
20.3
28
16
106
Kela drug reimbursment
Hypoparathyroidism
+∞
19.7
18
*
A12AA04
ATC
calcium carbonate; oral
126.1
18.5
19
*
A10AB05
ATC
insulin aspart; parenteral (insulins and analog. for injection, fast-acting)
18.1
17.5
28
24
H03AA01
ATC
levothyroxine sodium; systemic
8.9
16.4
45
111
E31.08
ICD-10 Finland
Autoimmune polyglandular failure
+∞
16.2
15
*
A10AC01
ATC
insulin (human); parenteral (insulins and analog. for injection, intermediate-acting)
18.3
15.9
25
20
A10AB04
ATC
insulin lispro; parenteral (insulins and analog. for injection, fast-acting)
29.9
15.2
20
9
103
Kela drug reimbursment
Diabetes, insulin-treated
8.3
15.0
41
97
T89
ICPC
Diabetes insulin dependent
22.1
14.5
21
13
A10AE04
ATC
insulin glargine; parenteral
11.9
14.4
28
36
215
Kela drug reimbursment
Diabetes, non-insulin-treated
7.9
14.1
39
92
E31.9
ICD-10 Finland
Polyglandular dysfunction, unspecified
+∞
14.0
13
*
E83.51
ICD-10 Finland
Hypocalcemia
155.7
12.9
13
*
A10AB01
ATC
insulin (human); parenteral (insulins and analog. for injection, fast-acting)
21.2
12.4
18
11
A11CC02
ATC
dihydrotachysterol; oral
+∞
11.8
11
*
E10.7
ICD-10 Finland
Type 1 diabetes mellitus, With multiple complications
42.5
11.7
14
*
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
6.3
11.1
36
98
H04AA01
ATC
glucagon; nasal, parenteral
20.0
11.0
16
10
E10.1
ICD-10 Finland
Type 1 diabetes mellitus, With ketoacidosis
38.9
10.7
13
*
E34.9
ICD-10 Finland
Endocrine disorder, unspecified
+∞
9.6
9
*
A12AA06
ATC
calcium lactate gluconate; oral
+∞
9.6
9
*
E31.1
ICD-10 Finland
Polyglandular hyperfunction
+∞
9.6
9
*
25810
ICD-8 Finland
Polyglandular dysfunction and other diseases of endocrine glands, Polyglandular dysfunction
+∞
9.6
9
*
104
Kela drug reimbursment
Thyroid insufficiency
11.0
9.5
18
21
A07AA02
ATC
nystatin; oral
11.9
9.4
17
18
XCK10
NOMESCO Finland
Photography of fundus of eye
8.5
9.4
21
33
E03.80
ICD-10 Finland
Hypothyroidism caused by autoimmune thyroiditis
22.2
9.3
13
7
E10.3
ICD-10 Finland
Type 1 diabetes mellitus, With ophthalmic complications
19.4
8.9
13
8
H36.09*E10.3
ICD-10 Finland
Insulin-dependent diabetes mellitus - Diabetic retinopathy
57.1
8.9
10
*
E03.89
ICD-10 Finland
Other specified hypothyroidism
31.8
8.8
11
*
E31.01
ICD-10 Finland
Schmidt's syndrome
+∞
8.5
8
*
E10.2
ICD-10 Finland
Type 1 diabetes mellitus, With renal complications
+∞
8.5
8
*
Z71.3
ICD-10 Finland
Dietary counselling and surveillance
20.1
8.4
12
7
E10.00
ICD-10 Finland
Insulin-dependent diabetes diabetic hypoglycemic coma
38.0
8.3
10
*
E87.6
ICD-10 Finland
Hypokalaemia
38.0
8.3
10
*
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
4.5
8.3
37
135
E03.9
ICD-10 Finland
Hypothyroidism, unspecified
6.5
8.2
22
45
A10AA01
ATC
NA
21.2
7.9
11
6
WZC00
NOMESCO Finland
Planning of intervention or health care consultation
4.3
7.9
38
147
A09AA02
ATC
multienzymes (lipase, protease etc.)
28.5
7.8
10
*
C03CA01
ATC
furosemide; systemic
4.8
7.6
28
83
2581B
ICD-9 Finland
Polyglandular dysfunction and related disorders, Other combinations of endocrine dysfunction[AUTOIMMUNE-POLYENDOCRINOPATHY-CANDIDOSIS-ECTOD DYST]
+∞
7.4
7
*
E31.8
ICD-10 Finland
Other polyglandular dysfunction
+∞
7.4
7
*
E31.0
ICD-10 Finland
Autoimmune polyglandular failure
+∞
7.4
7
*
25510
ICD-8 Finland
Diseases of adrenal glands, Adrenal cortical hypofunction
+∞
7.4
7
*
2581A
ICD-9 Finland
Polyglandular dysfunction and related disorders, Other combinations of endocrine dysfunction[SYNDROMA SCHMIDT]
+∞
7.4
7
*
SPAT1262
SPAT
Handing over of treatment supplies
5.1
7.4
25
67
133
Kela drug reimbursment
Severe chronic pancreatic insufficiency
33.7
7.3
9
*
E87.1
ICD-10 Finland
Hypo-osmolality and hyponatraemia
12.8
7.1
12
11
J01MA12
ATC
levofloxacin; systemic
5.4
7.0
22
54
A10AA02
ATC
NA
19.0
7.0
10
6
H3601, E103
ICD-10 Finland
NA
44.2
6.9
8
*
E83.50
ICD-10 Finland
Hypercalcemia
44.2
6.9
8
*
A10AE06
ATC
insulin degludec; parenteral
16.3
6.6
10
7
D44.8
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Pluriglandular involvement
76.2
6.5
7
*
107
Kela drug reimbursment
Pernicious anaemia
20.2
6.4
9
5
E11.9
ICD-10 Finland
Type 2 diabetes mellitus, without complications
4.7
6.4
23
65
Z01.8
ICD-10 Finland
Other specified special examinations
4.2
6.3
26
84
E21.09
ICD-10 Finland
Other primary hyperparathyroidism
+∞
6.3
6
*
E27.2
ICD-10 Finland
Addisonian crisis
+∞
6.3
6
*
L03.0
ICD-10 Finland
Cellulitis of finger and toe
7.6
6.2
14
22
121
Kela drug reimbursment
Severe hypofunction of sexual glands
16.8
6.1
9
6
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
28
45
8.66
17.99
17.2
3.1
1.2
1.2
mmol/l
0.61
28
39
71
296
8.24
16.94
32.7
9.3
1.2
1.2
mmol/l
2.86
59
252
50
176
5.26
13.70
7.4
4.0
17.1
8.2
mg/mmol
0.49
33
107
15
15
11.85
13.51
10.3
1.4
5.3
5.0
kpa
0.48
15
15
20
34
7.32
11.93
11.3
8.4
26.2
25.5
mmol/l
0.21
20
34
29
75
5.28
11.21
6.3
2.2
21.6
21.6
%
0.00
24
63
52
226
4.18
10.04
4.2
1.9
98.6
100.6
pmol/l
0.11
36
109
21
49
5.32
8.98
7.0
6.9
5.9
5.8
kpa
0.18
21
49
10
6
18.54
6.92
7.2
3.7
2.1
1.1
nmol/l
—
10
6
40
188
3.07
6.12
1.9
1.4
0.8
2.1
u/ml
0.58
11
48
20
61
3.95
6.02
4.1
3.1
—
—
—
0
0
8
5
17.38
5.52
4.6
1.4
—
—
—
0
0
25
101
3.06
4.84
3.6
1.8
—
—
—
0
0
42
231
2.57
4.47
7.9
2.8
—
—
—
0
0
9
13
7.57
4.28
1.7
2.5
—
—
—
0
0
6
5
12.73
3.82
1.7
1.2
—
—
—
0
0
10
25
4.38
3.81
8.3
4.2
62.0
51.4
%
—
10
25
8
12
7.20
3.76
10.3
1.5
60.0
57.2
%
—
8
12
13
41
3.55
3.66
1.7
1.5
—
—
—
0
0
10
27
4.05
3.46
2.2
1.7
—
—
—
0
0
40
237
2.26
3.40
5.4
3.8
24.6
18.5
ng/l
0.58
31
142
35
198
2.27
3.30
6.0
3.9
0.0
0.0
estimate
0.00
18
73
10
28
3.90
3.30
5.3
7.8
2.0
1.1
%
—
10
28
7
11
6.80
3.25
3.4
1.9
—
—
—
0
0
15
57
2.97
3.15
10.4
16.9
114.1
123.6
g/l
1.24
15
57
9
21
4.65
3.09
1.3
1.1
—
—
—
0
0
7
12
6.23
3.08
3.4
2.1
—
—
—
0
0
5
5
10.49
3.01
4.4
1.2
12.4
16.9
ug/l
—
5
5
10
30
3.63
3.01
17.5
3.4
25.5
25.5
mmol/l
—
10
30
29
158
2.25
2.95
3.1
3.7
1275.8
850.9
ng/l
0.50
23
136
7
13
5.75
2.93
3.4
1.9
—
—
—
0
0
7
14
5.33
2.79
3.4
2.0
—
—
—
0
0
6
10
6.34
2.74
1.7
1.0
—
—
—
0
0
7
16
4.65
2.53
1.1
1.4
—
—
—
0
0
5
8
6.54
2.40
1.0
1.0
—
—
—
0
0
11
41
2.92
2.38
10.2
7.6
0.8
0.8
%
0.00
11
41
8
23
3.72
2.33
3.1
2.0
—
—
—
0
0
28
164
2.04
2.31
3.1
1.8
1.3
1.1
mg/l
0.09
23
125
11
42
2.85
2.28
10.2
7.5
1.4
1.7
%
0.33
11
42
8
24
3.56
2.24
3.9
2.3
—
—
—
0
0
6
14
4.51
2.19
4.0
1.9
—
—
—
0
0
6
14
4.51
2.19
1.2
7.4
—
—
—
0
0
15
70
2.38
2.13
3.0
1.7
—
—
—
0
0
81
713
2.71
2.08
46.3
13.9
139.2
139.6
mmol/l
0.79
81
695
44
314
1.80
1.95
5.3
4.6
—
—
—
0
0
81
716
2.65
1.92
46.6
14.0
3.9
3.9
mmol/l
0.09
81
698
14
67
2.30
1.88
3.1
1.6
—
—
—
0
0
7
23
3.21
1.84
3.4
2.7
4.0
3.8
g/l
—
7
23
36
247
1.77
1.79
3.4
2.8
37.0
30.4
u/l
0.57
36
236
6
18
3.50
1.78
4.0
1.8
—
—
—
0
0
6
18
3.50
1.78
4.0
1.8
—
—
—
0
0
39
282
1.69
1.57
6.7
3.7
—
—
—
0
0
5
15
3.47
1.54
3.8
2.6
23.4
27.5
ug/min
—
5
8
9
37
2.59
1.53
1.6
1.2
—
—
—
0
0
46
352
1.64
1.47
7.7
5.2
0.0
0.0
estimate
0.00
19
72
5
16
3.25
1.46
2.0
1.8
—
—
—
0
0
5
17
3.05
1.38
2.6
2.6
—
—
—
0
0
46
356
1.61
1.37
6.4
3.9
0.0
0.0
estimate
0.49
17
69
46
356
1.61
1.37
6.3
3.7
0.0
0.0
estimate
0.00
20
74
6
24
2.61
1.33
3.5
1.3
52.7
32.9
nmol/l
—
6
24
6
26
2.40
1.21
1.2
1.1
—
—
—
0
0
22
151
1.61
1.04
3.7
2.2
—
—
—
0
0
17
113
1.63
0.90
4.2
4.4
1.0
1.9
ug/l
2.09
17
101
6
31
2.00
0.86
1.5
1.6
—
—
—
0
0
16
108
1.59
0.80
2.8
2.7
0.1
1.1
e6/l
3.64
11
62
5
23
2.24
0.77
1.2
1.3
—
—
—
0
0
5
24
2.15
0.76
9.0
2.8
233.8
198.4
%
—
5
24
5
25
2.06
0.74
2.0
2.2
—
—
—
0
0
15
102
1.57
0.73
3.1
2.9
1.1
4.9
e6/l
—
10
56
9
139
0.61
0.67
2.0
2.4
—
—
—
0
0
12
80
1.58
0.63
2.6
2.4
6.3
4.3
umol/l
0.67
12
71
0
20
0.00
0.61
0.0
1.1
—
1.9
—
0
8
6
39
1.58
0.54
3.2
1.9
0.0
0.0
e6/l
—
6
39
7
47
1.53
0.49
1.1
1.0
—
—
—
0
0
9
127
0.68
0.47
1.8
2.2
—
—
—
0
0
14
179
0.74
0.40
2.1
1.6
—
—
—
0
0
76
724
1.36
0.38
33.6
12.8
16.6
20.8
mg/l
0.97
68
547
18
149
1.26
0.31
1.9
1.5
—
—
—
0
0
16
131
1.27
0.30
1.4
1.3
1.2
8.0
u/ml
—
6
66
69
717
0.83
0.24
8.0
4.3
2.5
2.8
mmol/l
1.84
63
667
59
560
1.16
0.22
3.6
3.6
—
—
—
0
0
0
14
0.00
0.20
0.0
1.2
—
7.5
—
0
7
10
84
1.21
0.14
23.8
8.1
—
—
—
0
0
69
706
0.90
0.10
7.6
3.9
4.5
4.7
mmol/l
0.96
64
661
69
703
0.91
0.07
7.3
3.9
1.6
1.5
mmol/l
0.97
64
657
67
673
0.98
0.00
6.6
3.6
1.2
1.2
mmol/l
0.21
62
626
0
6
0.00
0.00
0.0
1.5
—
13.5
—
0
6
0
7
0.00
0.00
0.0
4.9
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
10.0
—
0
5
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.7
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
0.3
—
0
5
0
8
0.00
0.00
0.0
4.0
—
138.7
—
0
8
Mortality – FinRegistry
↥Association
Association between endpoint E4_DYSPOLYGL and mortality.
Females
No dataMales
No dataMortality risk
Mortality risk for people of age
years, who have E4_DYSPOLYGL.| N-year risk | Females | Males |
|---|---|---|
| 1 | No data | No data |
| 5 | No data | No data |
| 10 | No data | No data |
| 15 | No data | No data |
| 20 | No data | No data |
Relationships between endpoints
↥Index endpoint: E4_DYSPOLYGL – Polyglandular dysfunction
GWS hits: 2
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data